Published in PLoS One on June 12, 2012
Wee1 kinase as a target for cancer therapy. Cell Cycle (2013) 1.22
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer (2013) 1.05
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res (2014) 1.05
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia (2014) 0.97
Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol (2015) 0.92
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol (2013) 0.85
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer (2013) 0.85
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer (2015) 0.84
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol (2013) 0.83
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet (2013) 0.80
Targeting lung cancer through inhibition of checkpoint kinases. Front Genet (2015) 0.79
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget (2016) 0.78
A small molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther (2017) 0.76
Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability. Cell Cycle (2012) 0.76
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase. ACS Med Chem Lett (2014) 0.75
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma. Cancer Med (2015) 0.75
"Ready, set, go": checkpoint regulation by Cdk1 inhibitory phosphorylation. Fly (Austin) (2014) 0.75
MicroRNA-219-5p Inhibits Morphine-Induced Apoptosis by Targeting Key Cell Cycle Regulator WEE1. Med Sci Monit (2016) 0.75
WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett (2017) 0.75
Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. Oncol Lett (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell (1987) 8.76
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell (2007) 4.01
gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia (2010) 3.46
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol (2010) 2.43
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer (2008) 2.33
Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle (2006) 2.30
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal (2010) 2.27
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell (2010) 1.94
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res (2001) 1.80
Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res (2011) 1.78
WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res (2011) 1.59
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol (2001) 1.54
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol (2011) 1.53
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol (2004) 1.52
How protein kinases co-ordinate mitosis in animal cells. Biochem J (2011) 1.41
Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One (2009) 1.33
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology (2006) 1.25
A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer (1988) 1.21
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res (2000) 1.19
Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer (2006) 1.19
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer (2011) 1.18
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol (1998) 1.17
WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer (2011) 1.01
Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene (1999) 0.98
Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer (2006) 0.95
In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther (1997) 0.93
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol (1996) 0.92
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res (2004) 0.92
Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer (1998) 0.87
Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome. Melanoma Res (1995) 0.84
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Mod Pathol (2011) 2.08
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics (2006) 1.37
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol (2006) 1.36
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res (2003) 1.26
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol (2007) 1.23
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer (2004) 1.22
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer (2007) 1.16
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol (2005) 1.16
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol (2007) 1.16
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2006) 1.14
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol (2005) 1.09
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer (2012) 1.09
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol (2003) 1.06
1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin. Bioorg Med Chem (2008) 1.06
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res (2003) 1.05
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol (2004) 1.03
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep (2010) 1.02
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res (2012) 1.02
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol (2009) 1.00
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol (2005) 0.99
The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors. PLoS One (2011) 0.99
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res (2003) 0.98
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol (2004) 0.98
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer (2008) 0.98
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer (2007) 0.98
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res (2006) 0.97
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol (2008) 0.97
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochem Biophys Res Commun (2005) 0.96
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene (2002) 0.95
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol (2013) 0.95
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer (2008) 0.95
Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol (2006) 0.95
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer (2008) 0.95
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer (2010) 0.94
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness. Histopathology (2012) 0.94
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol (2011) 0.92
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia (2003) 0.92
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch (2006) 0.92
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat (2004) 0.91
Fli-1 expression in malignant melanoma. Histol Histopathol (2008) 0.91
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas. Gynecol Oncol (2004) 0.90
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol (2007) 0.90
WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas. Gastroenterology (2003) 0.90
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol (2005) 0.90
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential. Clin Sarcoma Res (2011) 0.89
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol (2012) 0.89
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res (2014) 0.89
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer (2012) 0.88
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer. Clin Cancer Res (2011) 0.88
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol (2006) 0.87
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol (2009) 0.87
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol (2013) 0.86
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators. Int J Surg Pathol (2003) 0.86
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One (2012) 0.86
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol (2009) 0.86
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch (2012) 0.86
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer (2013) 0.85
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer. Int J Radiat Oncol Biol Phys (2013) 0.84
Cyclins D1, D3, E, and A in vulvar carcinoma patients. Gynecol Oncol (2005) 0.83
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res (2004) 0.83
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. Am J Clin Pathol (2007) 0.83
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biol Ther (2011) 0.83
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer (2013) 0.83
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol (2004) 0.82
E-cadherin and catenins in early squamous cervical carcinoma. Gynecol Oncol (2004) 0.82
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
Occult lymph node metastases in early stage vulvar carcinoma patients. Gynecol Oncol (2005) 0.82
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer (2004) 0.81
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol (2005) 0.81
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer. Radiother Oncol (2011) 0.79
Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol (2004) 0.79
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Hum Pathol (2012) 0.79
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index. Cancer Chemother Pharmacol (2012) 0.79
Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett (2010) 0.79
Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis. Cancer Res (2002) 0.78
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Gynecol Oncol (2012) 0.78
Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice. Toxicology (2002) 0.77
Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients. Acta Oncol (2002) 0.77